Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Marcin Gondek
Chief Financial Officer of FutureMeds
Follow Marcin Gondek:
About FutureMeds: FutureMeds is a network of modern, dedicated clinical research sites that conduct clinical trials.
Keith Lovell
CFO of Antidote.me
Keith Lovell brings over 15 years’ experience gained from commercial, financial and management positions in a range of blue-chip, entrepreneurial and start-up organisations. Prior to Shazam at Extreme Mobile, Keith played an integral role in formulating commercial and financial plans for an MNVO venture with Vodafone. Previously, he was also responsible for all major network operator and supplier relationships at DX Communications Ltd and played a key role in negotiating the sale of the UK retail business to BT Cellnet, now 02.
Follow Keith Lovell:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Duncan Kennedy
Chief Financial Officer of BTG International
Duncan Kennedy joined BTG in December 2005 as Group Financial Controller and in April 2012 he joined the Leadership Team as Group Director of Finance, with management responsibility for the global finance function. Duncan led BTG’s Interventional Oncology business from May 2015 until he began as CFO in January 2018. Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc, an international leisure group, gaining wide-ranging experience in all aspects of listed company financial reporting and significant involvement in corporate transactions. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.
Follow Duncan Kennedy:
About BTG International: BTG is a global healthcare company focused on Interventional Medicine.
Adeel Ahmad
Chief Financial Officer of Advanz Pharma
Follow Adeel Ahmad:
About Advanz Pharma: ADVANZ PHARMA is a pharmaceutical company focused on serving the needs of patients and healthcare providers.
Andrew McMeeking
CFO of Prescient Healthcare Group
Andrew joined Prescient’s team in 2012 after holding finance director positions in marketing services companies such as Publicis and Gyro. He is a qualified chartered accountant and holds an honors degree in accountancy from Dundee University. He manages Prescient’s finances and is the company secretary. He was heavily involved in setting up the shared resources service center in the UK and arranging Prescient’s de-merger/MBO in 2014.
Follow Andrew McMeeking:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Paul Hayes
Chief Financial Officer of Consort Medical
Group Finance Director, British, aged 49, appointed to the Board on 13 June 2011. Previously he was Group Financial Controller at Signet Jewellers Limited (formerly Signet Group plc) between 2007 and 2011. Prior to that, he held a senior role at RHM plc from 2004 to 2007, through its flotation in 2005 and subsequent sale to Premier Foods plc. Paul was with Smiths Group plc for over ten years from 1993, including a number of divisional and operating company finance director roles. He is a Chartered Accountant having qualified with EY, and has a first class Masters degree in Mechanical Engineering, Manufacture & Management.
Follow Paul Hayes:
About Consort Medical, Vitec Group: Consort Medical offers medical device technologies for drug delivery and hospital products for the management of patient airways.
Didier Le Normand
Chief Financial Officer of Minoryx Therapeutics
Didier Le Normand graduated from the ESLSCA Paris business school (F) and holds a MBA degree from Pace University NY (USA). After a start of his career in banking, both United States and France, he moved to industrial corporate environments. Now he has a 20 year CFO experience, Finance and Operations, for private equity and venture backed private and listed companies in Europe, particularly in the Technology and Healthcare sectors. Over the past ten years Didier worked for Novagali Pharma (listed ophthalmic Biotech sold to Santen Pharma Japan), Cellnovo (listed Medtech, diabetes management systems) and, in his previous role, for STAT-DX (Spanish private medical diagnostic, successful sale to Qiagen in April 2018).
Follow Didier Le Normand:
About Minoryx Therapeutics: Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.
Robin Sibson
CFO of Clinigen Group
Follow Robin Sibson:
About Clinigen Group: Clinigen is a rapidly-growing specialty pharmaceutical and services company,
Jiahao Huang
Co-founder, Director and CFO of Nuclera
A molecular biologist by trade, Jiahao has coordinated multi-national collaborative projects and experienced first hand the limitations of the current provision of DNA. This intimate knowledge of user requirements enables him to guide Nuclera’s commercial operations towards creating the right product for the right market. Jiahao holds a BSc from the University of California, Berkeley, and a PhD in Molecular Biology from the University of Cambridge.
Follow Jiahao Huang:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Dawn Watson
Chief Financial Officer of AMR Centre
Experienced Financial Director of both high potential start-ups and established businesses across a broad range of industries. Having trained with Ernst & Young and after gaining many years in industry established her own company in 2010, FinStra Ltd, to provide strategic and financial support either as a part time or ad hoc Finance Director together with undertaking specific projects to help companies achieve their full potential.
Follow Dawn Watson:
About AMR Centre: AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics.
John A. Tattory
Chief Financial Officer of Windtree Therapeutics
Joined Discovery Labs in January 2008 and serves as Discovery Labs’ Senior Vice President and Chief Financial Officer, after several years as Vice President, Finance and Chief Accounting Officer. Mr. Tattory brings to Discovery Labs more than 20 years of finance and accounting experience, including eight years as a CPA and auditor at Ernst & Young LLP and eight years at Bristol-Myers Squibb (BMS) managing financial matters for various BMS pharmaceutical businesses including international operations. Mr. Tattory is currently responsible for managing the Company’s financial and accounting operations, including financial planning and forecasting, financial analysis, accounting systems and policies, internal controls, commercial accounting matters including sales forecasting and product pricing, cost accounting, and financial reporting.
Follow John A. Tattory:
About Windtree Therapeutics: Windtree is a clinical-stage focused on developing novel surfactant therapies for respiratory diseases and other potential applications.
